Citigroup | GenomeWeb

Citigroup

NEW YORK (GenomeWeb) – Citigroup this week initiated coverage of Cepheid with a Buy rating and a price target on its shares of $52.

NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citigroup upgraded Life Technologies to Buy today following last week's contraction in the company's stock price.

Analyst Amit Bhalla said that trade-in revenue from customers who purchase the HiSeq 2000 platform would not be a "significant contributor," and trimmed total revenue estimates for the second quarter and full-year 2011.

The bank also placed a price target of $52 on Illumina's stock.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.